Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs ShapeIn Rx

Claya
Graded #268

Higher grade

vs+2.3999999999999986
ShapeIn Rx
Graded #325

Lower grade

The verdict

Claya takes it — 62.8/100 to 60.4/100.

Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueShapeIn Rx +32
42
74
Dose & formulationClaya +18
75
57
Clinical oversightClaya +22
82
60
Labs & monitoringClaya +1
53
52
FulfillmentClaya +5
67
62
Contract termsClaya +20
61
41
Claya · left barShapeIn Rx · right bar

The numbers

MetricClayaShapeIn Rx
WeighScore62.8/10060.4/100
GradeCC
Scorecard rank#268#325
Semaglutide$299/mo (compounded)$199/mo (compounded)
Tirzepatide$299/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Claya

Graded #268 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
ShapeIn Rx

Graded #325 · C

Strengths

  • One of the few telehealth providers offering compounded liraglutide as a daily alternative to weekly injections
  • Semaglutide is compounded with B12, and the combination is stated plainly
  • Publishes a street address and a staffed phone line with hours
  • States openly that telemedicine is limited to jurisdictions where its providers are licensed, rather than claiming all 50
  • LegitScript certification verified against the issued seal, not just the badge

Where it loses points

  • Advertises Trusted by 150k Americans and Excellent 4.8 with 150k happy customers, and neither figure is attributable to a verifiable review profile
  • No state list is published, only a statement that coverage is limited and a note that partner pharmacies may operate in all 50 states
  • The struck-through $199 next to $149 on the homepage reads as a discount but the two prices are different medications
  • Claims No Hidden Fees and No Monthly Membership while the Terms state subscriptions automatically renew
  • No compounding pharmacy is named, only US-Certified Pharmacy

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard